Lutris updates
News & Announcements
Updates on our clinical programs, corporate milestones, and financing.
Lutris Pharma's Founder and Chairman of the Board Receives $5.0 Million Grant from the California Institute of Regenerative Medicine (CIRM) to Develop LUT017 for Wound Healing
Lutris Pharma Receives Notice of Allowance for Patent Covering the Use of B-RAF Inhibitors in MEK Inhibitor induced rash
Lutris Pharma Reports Positive Top-Line Results From the Open Label Part 1 and Double Blinded Part 2 of Its Phase 1/2 Trial of LUT014 to Treat Radiation Dermatitis in Patients with Breast Cancer
Lutris Pharma Appoints Company Founder, Antoni Ribas, M.D., Ph.D., as Chairman of the Board of Directors
Lutris Pharma to Present at the Bio€quity Europe Conference
Lutris Pharma Completes Enrollment of Part Two of its Phase 1/2 Trial of LUT014 To Treat Radiation Dermatitis in Patients with Breast Cancer
Lutris Pharma to Participate in Virtual Investor Conferences in January